ML604440 is a specific and cell-permeable Proteasome β1i ( LMP2 ) subunit inhibitor. ML604440 can be used in experimental colitis, EAE and autoimmune disease research. ML604440 shows synergistic effects and advantageous when combined with LMP7 inhibitor In Vitro ML604440 (300 nM; overnight) treatment shows no influence on the surface expression of H-2K b in wt or LMP7-deficient mice splenocytes. ML604440 (300 nM; 24 h) treatment shows no significant inhibition of IL-6 secretion by mouse splenocytes or human PBMCs. ML604440 (300 nM; 3 d) shows no influence on the percentage of IL-17A-producing CD4 + T cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo ML604440 (intraperitoneal injection; 10 mg/kg; once daily; 7 d) treatment inhibits LMP2 in vivo, shows no significant changes in platelet counts. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male C57BL/6J mice (6-8-wks old) injected with anti-platelet monoclonal antibodyDosage: 10 mg/kg Administration: Intraperitoneal injection; 10 mg/kg; once daily; 7 days Result: Inhibited LMP2 in vivo. Showed no significant improvement in platelet counts in mice immunized by monoclonal rat anti-mouse CD41 platelet antibody. Form:Solid IC50& Target:proteasome β1i (LMP2) subunit inhibitor